


# Journal Pre-proof

The Impact of Re-operation on Aortic Arch Reconstructive Surgery: Evidence from a Multicentre, National Registry

Chaoyi Qin, MD, Louis-Mathieu Stevens, MD, PhD, Rony Atoui, MD, MSc, Bindu Bittira, MD, John Bozinovski, MD, MSc, Munir Boodhwani, MD, MSc, Jennifer Chia-Ying Chung, MD, MSc, Francois Dagenais, MD, Phillippe Demers, MD, MSc, Ismail El-Hamamsy, MD, PhD, Ming Guo, MD, Jonathan Hong, MD, MHS, Kevin Lachapelle, MD, MSc, Michael Moon, MD, Maral Ouzounian, MD, PhD, Darrin Payne, MD, MSc, Mark D. Peterson, MD, PhD, Michael W.A. Chu, MD, MEd, Canadian Thoracic Aortic Collaborative



PII: S0022-5223(26)00770-1

DOI: <https://doi.org/10.1016/j.jtcvs.2026.03.572>

Reference: YMTC 20504

To appear in: *The Journal of Thoracic and Cardiovascular Surgery*

Received Date: 9 May 2025

Revised Date: 14 February 2026

Accepted Date: 8 March 2026



Please cite this article as: Qin C, Stevens L-M, Atoui R, Bittira B, Bozinovski J, Boodhwani M, Chia-Ying Chung J, Dagenais F, Demers P, El-Hamamsy I, Guo M, Hong J, Lachapelle K, Moon M, Ouzounian M, Payne D, Peterson MD, Chu MWA, Canadian Thoracic Aortic Collaborative, The Impact of Re-operation on Aortic Arch Reconstructive Surgery: Evidence from a Multicentre, National Registry, *The Journal of Thoracic and Cardiovascular Surgery* (2026), doi: <https://doi.org/10.1016/j.jtcvs.2026.03.572>.

This is a PDF of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability. This version will undergo additional copyediting, typesetting and review before it is published in its final form. As such, this version is no longer the Accepted Manuscript, but it is not yet the definitive Version of Record; we are providing this early version to give early visibility of the article. Please note that Elsevier's sharing policy for the Published Journal Article applies to this version, see: <https://www.elsevier.com/about/policies-and-standards/sharing#4-published-journal-article>. Please also note that, during the production process,

errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Copyright © 2026 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery

The Impact of Re-operation on Aortic Arch Reconstructive Surgery: a Multicentre, National Registry



	Primary	Redo	<i>p</i>
<b>HEMI-ARCH group</b>			
N.	1800	266	
Mortality	8.8 %	14 %	<b>0.014</b>
MMOM	29 %	33 %	0.104

	Primary	Redo	<i>p</i>
<b>TOTAL-ARCH group</b>			
N.	307	108	
Mortality	12 %	9.3 %	0.476
MMOM	42 %	42 %	0.976

From 2002 to 2021, nine centers

- **Primary** (2107) mortality: 9.3%
- **Redo-aortic** (246) mortality: 11%
- **Redo-other** (128) mortality: 14%

Independent predictors of mortality and MMOMs

Age over 65yrs

Acute dissection or rupture

Prolonged CPB time

Selected **aortic arch reoperations** can be performed safely in **experienced aortic centers** while further studies were needed for continuing optimization of surgical and patient management strategies.

1 The Impact of Re-operation on Aortic Arch Reconstructive Surgery: Evidence from a  
2 Multicentre, National Registry  
3 Chaoyi Qin, MD<sup>1,2</sup>, Louis-Mathieu Stevens, MD, PhD<sup>3</sup>, Rony Atoui, MD, MSc<sup>4</sup>, Bindu Bittira,  
4 MD<sup>4</sup>, John Bozinovski, MD, MSc<sup>5</sup>, Munir Boodhwani, MD, MSc<sup>6</sup>, Jennifer Chia-Ying Chung,  
5 MD, MSc<sup>7</sup>, Francois Dagenais, MD<sup>8</sup>, Phillippe Demers, MD, MSc<sup>9</sup>, Ismail EI-Hamamsy, MD,  
6 PhD<sup>10</sup>, Ming Guo, MD<sup>6</sup>, Jonathan Hong, MD, MHS<sup>11</sup>, Kevin Lachapelle, MD, MSc<sup>8</sup>, Michael  
7 Moon, MD<sup>12</sup>, Maral Ouzounian, MD, PhD,<sup>7</sup> Darrin Payne, MD, MSc<sup>13</sup>, Mark D Peterson, MD,  
8 PhD<sup>14</sup>, Michael W. A. Chu, MD, MEd<sup>1</sup>; Canadian Thoracic Aortic Collaborative  
9 <sup>1</sup>Division of Cardiac Surgery, Department of Surgery, Western University, London, ON, Canada.  
10 <sup>2</sup>Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu,  
11 Sichuan, China.  
12 <sup>3</sup>Division of Cardiac Surgery, University of Montreal, Montreal, Quebec, QC, Canada.  
13 <sup>4</sup>Department of Cardiac Surgery, Health Sciences North, Sudbury, Canada.  
14 <sup>5</sup> Division of Cardiac Surgery, Ohio State University Wexner Medical Center, Columbus, USA.  
15 <sup>6</sup>Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.  
16 <sup>7</sup>Division of Cardiac Surgery, Department of Surgery, University of Toronto, Toronto, Canada.  
17 <sup>8</sup>Division of Cardiac Surgery, Institut universitaire de cardiologie et de pneumologie de Québec  
18 (IUCPQ), Laval University, Laval, Canada.  
19 <sup>9</sup>Department of Cardiac Surgery, Montreal Heart Institute, Quebec, Canada.  
20 <sup>10</sup>Department of Cardiovascular Surgery, Icahn School of Medicine at Mount Sinai, New York,  
21 New York, USA.  
22 <sup>11</sup>Department of Cardiac Surgery, University of Manitoba, Canada.  
23 <sup>12</sup>Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada.

24 <sup>13</sup>Division of Cardiac Surgery, Department of Surgery, Queen's University, Kingston, Ontario,  
25 Canada.

26 <sup>14</sup>Division of Cardiothoracic Surgery, New York University Langone Medical Center, New York,  
27 USA.

28

29 **Disclosures:** MWC is supported as the Ray and Margaret Elliott Chair in Surgical Innovation  
30 and has received Speaker's honoraria from Medtronic, Edwards, Terumo Aortic and Artivion.

31 **Sources of Funding:** The authors received no financial support for the research, authorship,  
32 and/or publication of this article.

33 **Corresponding Author:**

34 Dr. Michael Chu, M.D., MEd, FRCSC, B6-106 University Hospital, 339 Windermere Road,  
35 London Health Sciences Centre, London Ontario, Canada, N6A 5A5. Department of Surgery,  
36 Division of Cardiac Surgery. [michael.chu@lhsc.on.ca](mailto:michael.chu@lhsc.on.ca); 519-663-3465

37 **Word Count:** 4016 words

38 **Institutional Review Board (IRB) Approval:** Ethics approval was obtained locally from  
39 institutional review boards at individual participating institutions, with data-sharing agreements  
40 with London Health Sciences Centre (REB #119869).

41 **Central message.**

42 Reoperative arch surgery is associated with similar operative mortality compared to primary  
43 surgery, but still remains risky in patients with advanced age, acute dissection and prolonged  
44 CPB time.

45 **Perspective Statement**

46 According to our multicenter, retrospective study, reoperative aortic arch reconstruction remains  
47 a high-risk and technically demanding operation, but can be performed safely and provides  
48 similar short-term outcomes to primary arch repair.

49

50 **This study was presented as an oral presentation at the AATS 2025 annual meeting in**  
51 **Seattle, WA.**

52

53

Journal Pre-proof

54 **Glossary of Abbreviations**

55 MMOM, a modified version of the Society of Thoracic Surgeons-defined composite endpoint for  
56 mortality and major morbidity;

57 CPB, cardiopulmonary bypass;

58 CTAC, Canadian Thoracic Aortic Collaborative;

59 HCA, hypothermic circulatory arrest;

60 ICU, intensive care unit;

61 LVEF, left ventricular ejection fraction;

62

63

64

Journal Pre-proof

**Abstract**

**Objective:** To analyze the in-hospital outcomes of patients undergoing re-operative aortic arch repair and identify risk factors for mortality and morbidity using data from a multicenter, national registry.

**Methods:** We collected data on patients undergoing aortic arch repair (hemiarch or total arch replacement with or without elephant trunk/frozen elephant trunk) under circulatory arrest between 2002 and 2021, including those with acute aortic dissection. Patients with a history of previous open-heart surgery were defined as the redo cases (aortic-redo group and other-redo group). The primary outcomes were operative mortality and a modified Society of Thoracic Surgeons composite endpoint for mortality and major morbidity (MMOM). The MMOM composite endpoint was defined as: operative mortality, stroke, dialysis-dependent renal failure, deep sternal wound infection, reoperation, prolonged ventilation of >40 hours. Blood transfusion rates were also analyzed.

**Results:** Overall, 374 (15%) of 2481 patients were in the redo cohort. The overall operative mortality of aortic arch reoperations was 12%. Although redo patients had a significantly higher comorbidity burden, no significant difference was identified for the operative mortality among primary, aortic-redo and other-redo groups (9.3% vs. 11% vs. 14%,  $p = 0.132$ ), and for the MMOM incidence (30% vs. 34% vs. 39%,  $p = 0.075$ ). Additionally, transfusion requirements and ICU/hospital stays were higher in both redo groups ( $p < 0.001$ ). To further analyze the redo group, all patients were divided into four groups: Primary hemi-arch group ( $n = 1800$ ), primary total-arch group ( $n = 307$ ), redo hemi-arch group ( $n = 266$ ) and redo total-arch group ( $n = 108$ ). Operative mortality was significantly higher in the redo hemi-arch group ( $p = 0.014$ ). In contrast, there was no significant difference in mortality or MMOM between primary and redo total-arch

88 groups ( $p > 0.05$ ). Multivariable analyses identified older age, acute aortic dissection, and  
89 prolonged CPB time (log-transformed) as independent predictors of both operative mortality and  
90 MMOM in reoperative arch repair.

91 **Conclusions:** This study of a national registry demonstrated that selected aortic arch  
92 reoperations can be performed with acceptable safety. Older age, acute aortic dissection, and  
93 prolonged CPB time are associated with worse operative outcomes. Further studies are needed to  
94 optimize surgical techniques and perioperative care, in addition to selecting patients who would  
95 benefit most from reoperative open arch surgery.

96  
97 Key words:

98 Reoperation, aortic arch reconstruction, outcomes, mortality

99

100

## 101 **Introduction**

102 Reoperations on aortic arch following previous aortic or cardiac surgery are increasingly  
103 common but remain challenging, with significant associated mortality and morbidity<sup>1,2</sup>. With the  
104 advanced aging population and improved long-term survival of primary cardiac or aortic surgery,  
105 the number of patients requiring reoperative aortic arch repair is increasing. Although there have  
106 been many iterative improvements in surgical techniques, strategies for myocardial protection  
107 and cerebral perfusion, and overall perioperative management, all attempting to reduce surgical  
108 risk, aortic arch reoperations are still associated with high complexity and operative mortality<sup>3</sup>.  
109 Aortic arch reoperations are technically demanding due to several factors: redo sternotomy,  
110 adhesions from prior cardiac or aortic surgery, complexity of aortic anatomy, and an older patient  
111 population with more comorbidities. In addition, most reoperative aortic arch repair cases are  
112 associated with prolonged cardiopulmonary bypass time and circulatory arrest time, challenging  
113 cerebral protection strategies, and malperfusion/reperfusion injury<sup>4</sup>. All these features contribute  
114 to the higher incidence of adverse events, including major bleeding, neurological complications,  
115 acute kidney injury and other end-organ dysfunction. The operative mortality of aortic arch  
116 reoperation remains high, ranging from 7%-15%<sup>1</sup>.

117 There are many previous studies examining reoperative aortic surgery, however, most consisted  
118 of small sample sizes, based on a single center or a single surgeon experience, which raises  
119 issues of reproducibility and generalizability.<sup>4,5</sup> We analyzed the short-term outcomes of all  
120 patients who had aortic arch reoperation from a multicenter, national registry. Patient  
121 characteristics and operative factors were also analyzed for identify independent predictors of  
122 mortality and morbidity.

123

**124 Methods***125 Study population*

126 The Canadian Thoracic Aortic Collaborative (CTAC) consists of nine participating centers and  
127 maintains a multicenter registry including inpatient data from all consecutive aortic procedures  
128 performed under circulatory arrest. Data is collected at local sites at the time of surgery and  
129 uploaded to the national registry periodically. Ethics approval was obtained locally from  
130 institutional review boards at individual participating institutions, with data-sharing agreements  
131 with Lawson Health Research Institute (IRB No. 119869; October 7, 2022).

132 All cases with aortic arch repair (hemiarch replacement, total arch replacement with or without  
133 elephant trunk) under circulatory arrest, including acute type A aortic dissection, were collected  
134 in our study from 2002 and 2021. Descending thoracic/thoracoabdominal aortic surgery using  
135 circulatory arrest were excluded. Hybrid aortic arch procedures were also included; however,  
136 details were not included for analysis. Redo cases were defined by any previous open heart  
137 surgery, including aortic, valvular, coronary artery, or other surgery . Specifically, patients with  
138 previous open aortic surgery were defined as the redo-aortic cohort and patients with open heart  
139 surgery, including valvular, coronary artery or other miscellaneous surgery under sternotomy or  
140 thoracotomy were defined as redo-other cohort.

*141 Operative strategies*

142 Cannulation strategies were carefully reviewed and reported in our previous study<sup>6</sup>. Briefly,  
143 strategies in our study included axillary, femoral, direct aortic, innominate and carotid artery  
144 cannulation. Each center selected the arterial cannulation site according to the patient specific  
145 pathological anatomy and institutional preference. Some patients (5%) had multiple cannulation  
146 strategies, including combining aortic cannulation, axillary cannulation and femoral cannulation.

147 Cerebral protection strategies were carefully reviewed and previously reported<sup>7</sup>. In general, most  
148 centers employed antegrade cerebral perfusion with moderate hypothermic circulatory arrest.  
149 Retrograde cerebral perfusion was used occasionally, and no brain perfusion was rarely  
150 employed. Neuromonitoring was used intra-operatively to further guide the brain protection  
151 strategies.

### 152 *Outcomes*

153 Two major outcomes were used in our study: operative mortality (in-hospital mortality or  
154 mortality within 30-days) and a modified version of the Society of Thoracic Surgeons-defined  
155 composite endpoint for mortality and major morbidity (MMOM). The MMOM composite  
156 endpoint was defined as the occurrence of one of the following endpoints: operative mortality,  
157 stroke, dialysis-dependent renal failure, deep sternal wound infection, reoperation, prolonged  
158 ventilation of >40 hours. Transfusion rates for patients undergoing arch reconstruction were also  
159 collected.

### 160 *Statistics*

161 Continuous variables were expressed as mean  $\pm$  standard deviation (SD) or median (interquartile  
162 range), and categorical variables were expressed as frequencies (%). Factors associated with the  
163 outcomes were identified logistic regression models using least absolute shrinkage and selection  
164 operator (LASSO) selection methods to identify candidate variables. Variables assessed as  
165 potential risk factors included pre-operative baseline characteristics (i.e., age, aortic valve  
166 disease, aortic diameter, presence of dissection or rupture, urgent status of surgery, and  
167 comorbidities), as well as operative data (extent of aortic reconstruction, concomitant surgeries,  
168 surgical times, hypothermic circulatory arrest (HCA) temperatures, HCA times, and cerebral  
169 protection strategies). For variables that were not normally distributed (e.g., surgical times), a

170 logarithmic transformation was used. To account for the effect of the individual centers,  
171 multivariable analyses using mixed effects regression models with logit link and a random effect  
172 of the center were then conducted using variables identified through LASSO (PROC GLIMMIX  
173 in SAS 9.4, SAS Institute, Cary, NC, USA). Variables were manually excluded in a backward  
174 selection process until all variables in the final model were significant.

175

## 176 **Results**

177 Overall, 374 of 2481 patients were included in the redo cohort. 246 patients had previous open-  
178 aortic surgery (redo-aortic group) and 128 had previous other open-heart surgery (redo-other  
179 group). The indications for reoperative aortic arch repair were analyzed and listed in the **Table 1**.

180 The most common indication for reoperation on aortic arch repair was degenerated aortic  
181 aneurysm (50.7%). The contribution of each centre to our redo cohort and respective mortalities  
182 were shown in the **Figure 1 and Supplementary Table 1**.

183 Demographic characteristics were listed in the **Table 2**. Mean age was  $63 \pm 13$  years and 32%  
184 were female. Patients in the aortic-redo group were younger and more often had connective  
185 tissue disease. Patients in both redo groups had a significant higher comorbidity burden, while  
186 patients in the other-redo group had worse heart function.

187 Intra-operative and outcomes data is shown in the **Table 3-4 and Supplementary Table 2**. No  
188 significant difference was identified for the operative mortality among primary, aortic-redo and  
189 other-redo groups (9.3% vs. 11% vs. 14%,  $p = 0.132$ ). Although patients in other-redo group  
190 more often experienced prolonged ventilation and renal failure requiring dialysis, no significant  
191 difference was confirmed for MMOM (30% vs. 34% vs. 39%,  $p = 0.075$ ).

192 In order to further analyze the redo group, all patients were divided into four groups: Primary  
193 hemi-arch group (n = 1800), primary total-arch group (n = 307), redo hemi-arch group (n = 266)  
194 and redo total-arch group (n = 108). Data was shown in the **Table 5** and **Supplementary Table**  
195 **3-5**. In the hemi-arch cohorts, redo patients had significantly higher operative mortality  
196 compared primary patients (14% vs. 8.8%,  $p = 0.014$ ). In the total-arch cohorts, no significant  
197 difference was found for operative mortality (12% vs. 9.3%,  $p = 0.476$ ) and MMOM  
198 complication rates (42% vs. 42%,  $p = 0.976$ ).

199 We performed multivariate analyses for independent predictors of operative mortality and  
200 MMOMs in both the whole cohort and redo cohort (Figure 2 and 3). Older age over 65, acute  
201 dissection or rupture and prolonged CPB time were identified as the independent predictors of  
202 operative mortality in patients with both primary and reoperative aortic arch repair.

203

## 204 **Discussion**

205 Most of the published evidence investigating outcomes in reoperative aortic arch surgery arise  
206 from a single center, often a single surgeon, which may reflect a specific and selective patient  
207 population, raising questions about generalizability. Our study analyzed 2481 patients who  
208 underwent aortic arch repair requiring circulatory arrest over the last two decades amongst nine  
209 Canadian centers with 374 patients identified as reoperative cases. The operative mortality rate  
210 was 12.3% and there were no significant differences in operative mortality between redo and  
211 primary aortic arch operations. Elderly patients (age over 65), acute dissection or rupture, and  
212 prolonged CPB time were identified as independent predictors of operative mortality in patients  
213 with both primary and reoperative aortic arch repair. This multi-center study from the major  
214 aortic centers in Canada included all patients with circulatory arrest arch repair. Our study

215 represents real world results with generalizable outcomes for re-operative surgery from an  
216 unselected patient population. Our study is also useful as a reference study to compare the  
217 outcomes to the burgeoning field of endovascular aortic arch repair.

218 Reoperative surgery of the aortic arch presents multiple technical challenges and is often  
219 performed in older patients with more comorbid risks, particularly in patients with prior aortic  
220 surgery. Although the operative mortality in our study may seem high at 12%, this patient  
221 population included all-comers including acute aortic dissection, prosthetic graft infections,  
222 aortic pseudoaneurysms and patients with high burden of comorbidities. We feel this mortality  
223 rate is more reflective of an unselected patient populations consistent with other publications <sup>1,4,8</sup>.

224 Some groups have published excellent results with reoperative aortic surgery, although patient  
225 selection may have been more stringent and the results are more reflective of single surgeon  
226 series. Ohira *et al.* recently reported their outcome of aortic reoperation after prior acute type A  
227 aortic dissection. A total of 123 reoperations were collected and revealed an average operative  
228 mortality rate of 2.4%, which included redo-sternotomy, left thoracotomy and endovascular  
229 approach<sup>5</sup>. Similar results were published by a high-volume center in China<sup>9</sup>. In our study, nine  
230 different volume centers were included and all patients requiring reoperative arch repair with  
231 redo-sternotomy were enrolled, including acute dissection, pseudoaneurysms and graft  
232 infections. Amongst the different centers, operative mortalities ranged from 0 to 24%. Not  
233 surprisingly, higher-volume centers demonstrated lower in-hospital mortalities, thus supporting  
234 the accruing evidence supporting the important volume-outcome relationship in aortic surgery.

235 Our previous study also demonstrated improved outcomes over time with rapid evolving of  
236 surgical strategies and perioperative management <sup>10</sup>.

237 Surprisingly, we found significantly higher operative mortality in redo hemi-arch group  
238 comparing with primary hemi-arch group while no significant difference between primary and  
239 redo total-arch cohort. We believe that this is largely related to the higher comorbidity in the redo  
240 hemiarch cohort. We hypothesize that the patients with higher comorbidity in the redo total-arch  
241 group were likely diverted to endovascular options, medical therapy or even towards hemiarch  
242 repair. The Bentall procedure for root repair, was also an independent predictor of operative  
243 mortality in our study. This is likely attributable to many factors, including more extensive aortic  
244 disease, complex aortic root re-operations, myocardial protection and technical challenges from  
245 re-operating on 'frozen' aortic roots<sup>11,12</sup>. Concomitant Bentall procedures were more common in  
246 the redo hemiarch group and may be another one of the reasons for the increased mortality seen  
247 in the redo hemiarch group compared to the redo total arch group.

248 In our study, the neurological complications remain high, ranging from 7.7% to 13%. However,  
249 we used a broad definition with included any neurological complications defined as stroke, TIA,  
250 seizures or any other central neurological complication. Several other studies also reported  
251 similar incidence of cerebrovascular event<sup>13-15</sup> Most patients received unilateral or bilateral  
252 antegrade cerebral perfusion during systemic hypothermic circulatory arrest. We did not identify  
253 any significant differences between antegrade and retrograde cerebral perfusion. Only a few  
254 patients received hypothermic circulatory arrest without cerebral perfusion and this strategy was  
255 an independent predictor of poor outcomes. In detail, our previous study about the impact of  
256 cerebral protection strategies confirmed that antegrade cerebral perfusion was a predictor of  
257 improved survival and neurological outcomes<sup>7</sup>. As for the impact of initial cannulation strategy  
258 on neurological outcomes, although the current study did not identify any significant difference,

259 our previous study found that axillary cannulation should be the preferred strategy in  
260 experienced centers if anatomy and stability allow<sup>6</sup>.

261 Recent studies have shown a higher reoperation rate after hemi-arch repair for acute type A aortic  
262 dissection<sup>16</sup>. Our group previously demonstrated that extended arch replacement can be  
263 performed with similar perioperative mortality and permanent neurologic risk as hemiarch repair  
264 in type A aortic dissection<sup>17</sup>. However, extended arch replacement should be offered to carefully  
265 selected patients due to increased risk of composite adverse events<sup>17</sup>. In order to further address  
266 these issues, our group initiated the first randomized trial in acute type A aortic dissection, the  
267 treatment in thoracic aortic aneurysm: hemiarch vs extended arch in aortic dissection—a  
268 systematic analysis by randomized trial (TITAN:HEADSTART), to provide evidence to  
269 determine the optimal arch strategy in acute type A dissection<sup>18</sup>.

270 Consistent with previous studies, we also found that older age, aortic dissection or rupture, and  
271 prolonged CPB time and were independent predictors of operative mortality<sup>8,12,19-21</sup>. Elderly  
272 patients have more comorbidities and frailty resulting in a lower reserve for withstanding  
273 complex aortic reconstructive surgery. Prolonged CPB time reflects the increased complexity of  
274 the operations and has been associated with both short-term and long-term clinical outcomes<sup>22-24</sup>.

275 We also performed our analysis using a composite outcome of MMOM, and found no significant  
276 differences between the primary and reoperative aortic arch repair.

277 Our study has several limitations. Firstly, the CTAC database focuses on short-term, in-hospital  
278 data that may have been prone to many known or unknown biases with no long-term follow-up  
279 data. Secondly, we lacked granular data on the specific details of the previous operations. There  
280 was also no central adjudication of adverse events such as neurological complications. Thirdly,

281 the absolute number of mortalities (46) in the redo setting was relatively low, hence, limiting our  
282 ability to perform a more comprehensive multivariable analysis.

283 In conclusion, this multicenter study from the major aortic centers in Canada demonstrated the  
284 real-world operative mortality of aortic arch reoperations to be 12.3%, without significant  
285 differences compared to primary arch operations. We found that older age, acute dissection or  
286 rupture and prolonged CPB time as independent predictors for both operative death and  
287 MMOMs. Reoperative arch surgery with concomitant a Bentall procedure was also an  
288 independent predictor for operative mortality. These high-risk patients would benefit from  
289 careful counselling in the shared-decision making process and consideration to alternative  
290 treatment strategies including endovascular or medical management. We believe that selected  
291 aortic arch reoperations can be performed safely in experienced aortic centers. Further studies are  
292 needed to identify specific surgical techniques and patient characteristics who would benefit  
293 the most from complex, reoperative aortic surgery.

294

295 **References**

- 296 1. Di Marco L, Gliozzi G, Votano D, et al. Reoperations on the ascending aorta and aortic  
297 arch: A retrospective series of 453 patients. *J Thorac Cardiovasc Surg*. Mar 2024;167(3):897-907  
298 e3. doi:10.1016/j.jtcvs.2022.03.039
- 299 2. Vekstein AM, Hughes GC, Chen EP. Open arch surgery in the redo setting: contemporary  
300 outcomes. *J Cardiovasc Surg (Torino)*. Aug 2022;63(4):415-424. doi:10.23736/S0021-  
301 9509.22.12388-8
- 302 3. Lou X, Leshnowar BG, Binongo J, Beckerman Z, McPherson L, Chen EP. Re-Operative  
303 Aortic Arch Surgery in a Contemporary Series. *Semin Thorac Cardiovasc Surg*. Summer  
304 2022;34(2):377-382. doi:10.1053/j.semtcvs.2021.03.035
- 305 4. Dietze Z, Kang J, Madomegov K, et al. Aortic arch redo surgery: early and mid-term  
306 outcomes in 120 patients. *Eur J Cardiothorac Surg*. Dec 1 2023;64(6)doi:10.1093/ejcts/ezad419
- 307 5. Ohira S, Malekan R, Kai M, et al. Aortic Reoperation After Prior Acute Type A Aortic  
308 Dissection Repair: Don't Despair the Repair. *Ann Thorac Surg*. Jul 2023;116(1):43-50.  
309 doi:10.1016/j.athoracsur.2022.10.021
- 310 6. Elbatarny M, Hage F, Zubair A, et al. Initial cannulation strategy impacts perioperative  
311 outcomes of acute type A dissection in high-volume centers. *J Thorac Cardiovasc Surg*. Oct 11  
312 2024;doi:10.1016/j.jtcvs.2024.09.056
- 313 7. Hage A, Stevens LM, Ouzounian M, et al. Impact of brain protection strategies on  
314 mortality and stroke in patients undergoing aortic arch repair with hypothermic circulatory  
315 arrest: evidence from the Canadian Thoracic Aortic Collaborative. *Eur J Cardiothorac Surg*. Jul 1  
316 2020;58(1):95-103. doi:10.1093/ejcts/ezaa023
- 317 8. Norton EL, Kalra K, Leshnowar BG, Wei JW, Binongo JN, Chen EP. Redo aortic surgery:  
318 Does one versus multiple affect outcomes? *JTCVS Open*. Dec 2023;16:158-166.  
319 doi:10.1016/j.xjon.2023.09.035
- 320 9. Gao F, Ge Y, Zhong Y, Zhuang X, Zhu J. Redo Total Aortic Arch Replacement in Patients  
321 with Aortic Dissection After Open-Heart Surgery and Long-Term Follow-Up Results. *Braz J*  
322 *Cardiovasc Surg*. Apr 23 2023;38(2):265-270. doi:10.21470/1678-9741-2022-0022
- 323 10. Ibrahim M, Stevens LM, Ouzounian M, et al. Evolving Surgical Techniques and Improving  
324 Outcomes for Aortic Arch Surgery in Canada. *CJC Open*. Sep 2021;3(9):1117-1124.  
325 doi:10.1016/j.cjco.2021.05.001
- 326 11. Brown JA, Serna-Gallegos D, Kilic A, et al. Outcomes of reoperative aortic root surgery. *J*  
327 *Thorac Cardiovasc Surg*. Sep 2023;166(3):716-724 e3. doi:10.1016/j.jtcvs.2021.09.060
- 328 12. Ogami T, Serna-Gallegos D, Arnaoutakis GJ, et al. The impact of reoperative surgery on  
329 aortic root replacement in the United States. *J Thorac Cardiovasc Surg*. Apr 2024;167(4):1185-  
330 1193 e1. doi:10.1016/j.jtcvs.2023.04.006
- 331 13. Zhang Y, Wang Y, Liu F, et al. Reoperative extended arch repair for acute type A aortic  
332 dissection after previous cardiac surgery: insights from a relatively young redo series. *Eur J*  
333 *Cardiothorac Surg*. Jul 1 2024;66(1)doi:10.1093/ejcts/ezae266
- 334 14. Nappi F, Petiot S, Salsano A, et al. Sex-Based Difference in Aortic Dissection Outcomes: A  
335 Multicenter Study. *J Cardiovasc Dev Dis*. Mar 30 2023;10(4)doi:10.3390/jcdd10040147

- 336 15. Lang Q, Zhang J, Li J, Xiao Z, Meng W, Qin C. Is Prior Cardiac Surgery a Risk Factor for  
337 Patients in Aortic Surgery: A Systematic Review and Meta-analysis. *J Cardiothorac Vasc Anesth.*  
338 Jul 2 2025;doi:10.1053/j.jvca.2025.06.056
- 339 16. Ma L, Chai T, Yang X, et al. Outcomes of hemi- vs. total arch replacement in acute type A  
340 aortic dissection: A systematic review and meta-analysis. *Front Cardiovasc Med.* 2022;9:988619.  
341 doi:10.3389/fcvm.2022.988619
- 342 17. Elbatarny M, Stevens LM, Dagenais F, et al. Hemiarch versus extended arch repair for  
343 acute type A dissection: Results from a multicenter national registry. *J Thorac Cardiovasc Surg.*  
344 Mar 2024;167(3):935-943 e5. doi:10.1016/j.jtcvs.2023.04.012
- 345 18. Elbatarny M, Boodhwani M, Chu MWA, Appoo JJ, Ouzounian M. Reply from authors:  
346 Prospective trials are required to determine the optimal arch strategy for acute type A  
347 dissection. *J Thorac Cardiovasc Surg.* Mar 2024;167(3):e65-e66. doi:10.1016/j.jtcvs.2023.09.003
- 348 19. Di Bartolomeo R, Berretta P, Petridis FD, et al. Reoperative surgery on the thoracic aorta.  
349 *J Thorac Cardiovasc Surg.* Mar 2013;145(3 Suppl):S78-84. doi:10.1016/j.jtcvs.2012.11.055
- 350 20. Etz CD, Plestis KA, Homann TM, et al. Reoperative aortic root and transverse arch  
351 procedures: a comparison with contemporaneous primary operations. *J Thorac Cardiovasc Surg.*  
352 Oct 2008;136(4):860-7, 867 e1-3. doi:10.1016/j.jtcvs.2007.11.071
- 353 21. Gambardella I, Gaudino M, Lau C, et al. Contemporary results of hemiarch replacement.  
354 *Eur J Cardiothorac Surg.* Aug 1 2017;52(2):333-338. doi:10.1093/ejcts/ezx071
- 355 22. Martins RS, Ukrani RD, Memon MK, Ahmad W, Akhtar S. Risk factors and outcomes of  
356 prolonged cardiopulmonary bypass time in surgery for adult congenital heart disease: a single-  
357 center study from a low-middle-income country. *J Cardiovasc Surg (Torino).* Aug 2021;62(4):399-  
358 407. doi:10.23736/S0021-9509.21.11583-6
- 359 23. LaPar DJ, Ailawadi G, Harris DA, et al. A protocol-driven approach to cardiac reoperation  
360 reduces mortality and cardiac injury at the time of resternotomy. *Ann Thorac Surg.* Sep  
361 2013;96(3):865-70; discussion 870. doi:10.1016/j.athoracsur.2013.03.061
- 362 24. Leone A, Beckmann E, Martens A, et al. Total aortic arch replacement with frozen  
363 elephant trunk technique: Results from two European institutes. *J Thorac Cardiovasc Surg.* Apr  
364 2020;159(4):1201-1211. doi:10.1016/j.jtcvs.2019.03.121
- 365

366

367 **Figure legends**

368 **Figure 1.** (a) Proportion of indications for reoperative aortic arch reconstructions. (b)

369 distribution and mortalities of nine participating centers in CTAC database.

370 **Figure 2.** Forest plot of multivariable logistic regression model for predictors of operative

371 mortality. Odds ratios (OR) with 95% confidence intervals (CI). (a) multivariate analyses for

372 operative mortality in the whole population; (b) multivariate analyses for MMOM in the whole

373 population.

374 **Figure 3.** Forest plot of multivariable logistic regression model for predictors of operative

375 mortality. Odds ratios (OR) with 95% confidence intervals (CI). (a) multivariate analyses for

376 operative mortality in the redo setting; (b) multivariate analyses for MMOM in the redo setting.

377 **Figure 4.** Graphical Abstract.

378 **Central picture.** No significant difference was identified among primary and redo groups.

379 **Supplementary video legend.** Reoperative total arch replacement with carotid artery

380 cannulation

381 **Audio:**

382 You can listen to the audio recording of the presentation and discussion associated with this

383 paper in supplementary materials.

384

Table 1. The indications for reoperative aortic arch repair.

	INDICATIONS					
	Degenerated aneurysm	Chronic or residual dissection	Pseudoaneurysm	Endocarditis	Acute dissection	Others
Total	190 (51%)	45 (12%)	34 (9.0%)	26 (7.0%)	64 (17%)	15 (4.1%)
HEMI-ARCH	153 (57%)	9 (3.2%)	19 (7.3%)	25 (9.3%)	46 (17%)	14 (5.3%)
TOTAL-ARCH	36 (34%)	38 (35%)	14 (13%)	1 (1.0%)	18 (16%)	1 (1.0%)

Table 2. Demographic characteristics.

Variable	OVERALL (N=2481)	PRIMARY (N=2107)	REDO-AORTIC (N=246)	REDO-OTHER (N=128)	P
Age, years	63 ± 13	64 ± 13	58 ± 16	65 ± 13	<.001
Female gender	32% (784)	33% (702)	25% (61)	16% (21)	<.001
Height, cm	1.7 ± 0.1	1.7 ± 0.1	1.7 ± 0.1	1.7 ± 0.1	0.008
Weight, kg	83 ± 19	83 ± 20	81 ± 18	82 ± 16	0.650
Body mass index	28 ± 6	28 ± 6	27 ± 5	28 ± 7	0.026
Hypertension	67% (1665)	68% (1428)	63% (156)	63% (81)	0.247
Diabetes	13% (313)	13% (272)	8.9% (22)	15% (19)	0.153
Dyslipidemia	45% (1112)	44% (928)	41% (101)	65% (83)	<.001
Preoperative renal failure	4.6% (114)	4.3% (90)	6.9% (17)	5.5% (7)	0.155
Cerebrovascular disease	7.1% (177)	6.2% (131)	13% (31)	12% (15)	<.001
Peripheral vascular disease	11% (268)	10% (216)	14% (35)	13% (17)	0.107
Ever smoker	45% (1107)	46% (960)	41% (101)	36% (46)	0.052
Chronic obstructive pulmonary disease	12% (298)	12% (250)	14% (35)	10% (13)	0.449
Preoperative atrial fibrillation	12% (297)	11% (227)	15% (37)	26% (33)	<.001
Coronary artery disease	21% (516)	19% (408)	22% (53)	43% (55)	<.001
Prior myocardial infarction	7.5% (185)	7.0% (147)	8.5% (21)	13% (17)	0.025
Congestive heart failure	11% (275)	10% (214)	16% (39)	17% (22)	0.002
Connective tissue disorder					<.001
- None	95% (2350)	96% (2017)	85% (209)	97% (124)	

Variable	OVERALL (N=2481)	PRIMARY (N=2107)	REDO-AORTIC (N=246)	REDO-OTHER (N=128)	P
- Confirmed	3.2% (79)	2.1% (44)	13% (33)	1.6% (2)	
- Suspected	2.1% (52)	2.2% (46)	1.6% (4)	1.6% (2)	
Left ventricular ejection fraction, %	56 ± 9	56 ± 9	56 ± 10	52 ± 11	<.001
Ascending aorta aneurysm	75% (1860)	74% (1562)	83% (204)	73% (94)	0.010
Acute Dissection or Rupture	30% (756)	34% (714)	6.9% (17)	20% (25)	<.001
PREOPERATIVE STATUS					
Urgency status					<.001
- Elective	57% (1411)	55% (1153)	73% (180)	61% (78)	
- Urgent (same hospital stay)	11% (264)	9.4% (199)	18% (44)	16% (21)	
- Emergent or salvage	32% (806)	36% (755)	8.9% (22)	23% (29)	
Preoperative NYHA class III or IV	18% (445)	17% (349)	21% (51)	35% (45)	<.001

Table 3. Intra-operative surgical details and perfusion data.

Variable	OVERALL (N=2481)	PRIMARY (N=2107)	REDO-AORTIC (N=246)	REDO-OTHER (N=128)	P
Concomitant aortic valve surgery	75% (1856)	77% (1617)	61% (149)	70% (90)	<.001
- Aortic valve replacement	20% (490)	20% (419)	17% (42)	23% (29)	0.403
- Bentall	27% (663)	26% (547)	30% (74)	33% (42)	0.107
- Ross	0.36% (9)	0.28% (6)	0.81% (2)	0.78% (1)	0.308
- Valve sparing root replacement	7.6% (189)	8.4% (177)	3.3% (8)	3.1% (4)	0.002
Ascending aorta replacement	87% (2163)	88% (1855)	79% (194)	89% (114)	<.001
Aortic arch surgery					<.001
- Hemiarch	83% (2066)	85% (1800)	61% (151)	90% (115)	
- Total arch	17% (415)	15% (307)	39% (95)	10% (13)	
Elephant trunk					<.001
- No elephant trunk	90% (2231)	92% (1928)	74% (181)	95% (122)	
- Conventional elephant trunk	4.6% (115)	3.9% (83)	12% (30)	1.6% (2)	
- Frozen elephant trunk	5.4% (135)	4.6% (96)	14% (35)	3.1% (4)	
Concomitant surgery	28% (684)	26% (543)	35% (87)	42% (54)	<.001
- Mitral valve replacement	2.1% (52)	1.4% (30)	4.9% (12)	7.8% (10)	<.001
- Mitral valve repair	2.1% (53)	1.9% (40)	3.7% (9)	3.1% (4)	0.143
- CABG	19% (475)	19% (400)	16% (39)	28% (36)	0.015
- ASD or VSD closure	1.5% (36)	1.5% (32)	1.2% (3)	0.78% (1)	0.755
PERFUSION DETAILS					

Variable	OVERALL (N=2481)	PRIMARY (N=2107)	REDO-AORTIC (N=246)	REDO-OTHER (N=128)	P
Arterial cannulation site					
- Axillary, innominate or carotid	74% (754)	74% (662)	71% (65)	75% (27)	0.724
- Aortic	30% (303)	30% (268)	24% (22)	36% (13)	0.323
- Femoral	14% (146)	13% (119)	25% (23)	11% (4)	0.009
Cardiopulmonary bypass time, min.	174 [129, 231]	170 [125, 222]	199 [162, 276]	206 [150, 266]	<.001
Myocardial ischemia time, min.	100 [67, 143]	99 [66, 140]	117 [67, 163]	106 [78, 154]	0.003
Deep hypothermic cardiac arrest time, min.	20 [13, 32]	20 [13, 31]	23 [15, 38]	19 [12, 29]	<.001
Lowest temperature, Celcius	24 [20, 26]	24 [20, 26]	22 [18, 25]	23 [19, 26]	<.001
Cerebral perfusion strategy					0.163
- No cerebral perfusion	15% (361)	14% (297)	15% (37)	21% (27)	
- Unilateral antegrade	75% (1863)	75% (1582)	76% (187)	73% (94)	
- Bilateral antegrade	4.0% (100)	4.1% (86)	4.5% (11)	2.3% (3)	
- Retrograde	6.3% (157)	6.7% (142)	4.5% (11)	3.1% (4)	

Table 4. Outcomes data.

Variable	OVERALL (N=2481)	PRIMARY (N=2107)	REDO-AORTIC (N=246)	REDO-OTHER (N=128)	P value
POSTOPERATIVE OUTCOMES					
- Hospital mortality	10% (241)	9.3% (195)	11% (28)	14% (18)	0.132
- Cardiac reoperation for tamponade or bleeding	9.4% (233)	9.0% (190)	12% (29)	11% (14)	0.306
- Prolonged ventilation (> 40h)	19% (473)	18% (382)	22% (55)	28% (36)	0.008
- Dialysis dependent renal failure	5.6% (138)	5.2% (109)	5.7% (14)	12% (15)	0.007
- Deep sternal wound infection	0.69% (17)	0.62% (13)	0.41% (1)	2.3% (3)	0.061
- Any cerebrovascular accident	10% (255)	10% (220)	7.7% (19)	13% (16)	0.288
- STS modified composite endpoint (death, stroke, reop, renal failure, DSWI, long vent. > 40h)	31% (776)	30% (642)	34% (84)	39% (50)	0.075

Table 5. Outcomes of subgroup analysis.

Variable	PRIMARY-HEMI (N=1800)	REDO-HEM (N=266)I	P value	PRIMARY-TOTAL (N=307)	REDO-TOTAL (N=108)	P value
POSTOPERATIVE OUTCOMES						
- Hospital mortality	8.8% (159)	14% (36)	0.014	12% (36)	9.3% (10)	0.476
- Cardiac reoperation for tamponade or bleeding	8.3% (149)	10% (27)	0.306	13% (41)	15% (16)	0.713
- Prolonged ventilation (> 40h)	17% (302)	23% (61)	0.014	26% (80)	28% (30)	0.741
- Dialysis dependent renal failure	4.7% (85)	7.9% (21)	0.028	7.8% (24)	7.4% (8)	0.884
- Deep sternal wound infection	0.67% (12)	1.1% (3)	0.408	0.33% (1)	0.93% (1)	0.440
- Any cerebrovascular accident	10% (182)	10% (26)	0.867	12% (38)	8.3% (9)	0.250
- STS modified composite endpoint (death, stroke, reop, renal failure, DSWI, long vent. > 40h)	29% (515)	33% (89)	0.104	41% (127)	42% (45)	0.976
INTENSIVE CARE AND HOSPITAL STAY						
ICU length of stay (first stay), d	2.0 [1.0, 5]	2.9 [1.2, 6]	0.002	3.0 [1.1, 6]	3.1 [1.5, 8]	0.545
Hospital length of stay (first stay), d	8 [6, 14]	9 [6, 18]	0.007	10 [7, 21]	13 [7, 18]	0.290

Table 1. The indications for reoperative aortic arch repair.

	INDICATIONS					
	Degenerated aneurysm	Chronic or residual dissection	Pseudoaneurysm	Endocarditis	Acute dissection	Others
Total	190 (51%)	45 (12%)	34 (9.0%)	26 (7.0%)	64 (17%)	15 (4.1%)
HEMI-ARCH	153 (57%)	9 (3.2%)	19 (7.3%)	25 (9.3%)	46 (17%)	14 (5.3%)
TOTAL-ARCH	36 (34%)	38 (35%)	14 (13%)	1 (1.0%)	18 (16%)	1 (1.0%)

Table 2. Demographic characteristics.

Variable	OVERALL (N=2481)	PRIMARY (N=2107)	REDO-AORTIC (N=246)	REDO-OTHER (N=128)	P
Age, years	63 ± 13	64 ± 13	58 ± 16	65 ± 13	<.001
Female gender	32% (784)	33% (702)	25% (61)	16% (21)	<.001
Height, cm	1.7 ± 0.1	1.7 ± 0.1	1.7 ± 0.1	1.7 ± 0.1	0.008
Weight, kg	83 ± 19	83 ± 20	81 ± 18	82 ± 16	0.650
Body mass index	28 ± 6	28 ± 6	27 ± 5	28 ± 7	0.026
Hypertension	67% (1665)	68% (1428)	63% (156)	63% (81)	0.247
Diabetes	13% (313)	13% (272)	8.9% (22)	15% (19)	0.153
Dyslipidemia	45% (1112)	44% (928)	41% (101)	65% (83)	<.001
Preoperative renal failure	4.6% (114)	4.3% (90)	6.9% (17)	5.5% (7)	0.155
Cerebrovascular disease	7.1% (177)	6.2% (131)	13% (31)	12% (15)	<.001
Peripheral vascular disease	11% (268)	10% (216)	14% (35)	13% (17)	0.107
Ever smoker	45% (1107)	46% (960)	41% (101)	36% (46)	0.052
Chronic obstructive pulmonary disease	12% (298)	12% (250)	14% (35)	10% (13)	0.449
Preoperative atrial fibrillation	12% (297)	11% (227)	15% (37)	26% (33)	<.001
Coronary artery disease	21% (516)	19% (408)	22% (53)	43% (55)	<.001
Prior myocardial infarction	7.5% (185)	7.0% (147)	8.5% (21)	13% (17)	0.025
Congestive heart failure	11% (275)	10% (214)	16% (39)	17% (22)	0.002
Connective tissue disorder					<.001
- None	95% (2350)	96% (2017)	85% (209)	97% (124)	

Variable	OVERALL (N=2481)	PRIMARY (N=2107)	REDO-AORTIC (N=246)	REDO-OTHER (N=128)	P
- Confirmed	3.2% (79)	2.1% (44)	13% (33)	1.6% (2)	
- Suspected	2.1% (52)	2.2% (46)	1.6% (4)	1.6% (2)	
Left ventricular ejection fraction, %	56 ± 9	56 ± 9	56 ± 10	52 ± 11	<.001
Ascending aorta aneurysm	75% (1860)	74% (1562)	83% (204)	73% (94)	0.010
Acute Dissection or Rupture	30% (756)	34% (714)	6.9% (17)	20% (25)	<.001
PREOPERATIVE STATUS					
Urgency status					<.001
- Elective	57% (1411)	55% (1153)	73% (180)	61% (78)	
- Urgent (same hospital stay)	11% (264)	9.4% (199)	18% (44)	16% (21)	
- Emergent or salvage	32% (806)	36% (755)	8.9% (22)	23% (29)	
Preoperative NYHA class III or IV	18% (445)	17% (349)	21% (51)	35% (45)	<.001

Table 3. Intra-operative surgical details and perfusion data.

Variable	OVERALL (N=2481)	PRIMARY (N=2107)	REDO-AORTIC (N=246)	REDO-OTHER (N=128)	P
Concomitant aortic valve surgery	75% (1856)	77% (1617)	61% (149)	70% (90)	<.001
- Aortic valve replacement	20% (490)	20% (419)	17% (42)	23% (29)	0.403
- Bentall	27% (663)	26% (547)	30% (74)	33% (42)	0.107
- Ross	0.36% (9)	0.28% (6)	0.81% (2)	0.78% (1)	0.308
- Valve sparing root replacement	7.6% (189)	8.4% (177)	3.3% (8)	3.1% (4)	0.002
Ascending aorta replacement	87% (2163)	88% (1855)	79% (194)	89% (114)	<.001
Aortic arch surgery					<.001
- Hemiarch	83% (2066)	85% (1800)	61% (151)	90% (115)	
- Total arch	17% (415)	15% (307)	39% (95)	10% (13)	
Elephant trunk					<.001
- No elephant trunk	90% (2231)	92% (1928)	74% (181)	95% (122)	
- Conventional elephant trunk	4.6% (115)	3.9% (83)	12% (30)	1.6% (2)	
- Frozen elephant trunk	5.4% (135)	4.6% (96)	14% (35)	3.1% (4)	
Concomitant surgery	28% (684)	26% (543)	35% (87)	42% (54)	<.001
- Mitral valve replacement	2.1% (52)	1.4% (30)	4.9% (12)	7.8% (10)	<.001
- Mitral valve repair	2.1% (53)	1.9% (40)	3.7% (9)	3.1% (4)	0.143
- CABG	19% (475)	19% (400)	16% (39)	28% (36)	0.015
- ASD or VSD closure	1.5% (36)	1.5% (32)	1.2% (3)	0.78% (1)	0.755
PERFUSION DETAILS					

Variable	OVERALL (N=2481)	PRIMARY (N=2107)	REDO-AORTIC (N=246)	REDO-OTHER (N=128)	P
Arterial cannulation site					
- Axillary, innominate or carotid	74% (754)	74% (662)	71% (65)	75% (27)	0.724
- Aortic	30% (303)	30% (268)	24% (22)	36% (13)	0.323
- Femoral	14% (146)	13% (119)	25% (23)	11% (4)	0.009
Cardiopulmonary bypass time, min.	174 [129, 231]	170 [125, 222]	199 [162, 276]	206 [150, 266]	<.001
Myocardial ischemia time, min.	100 [67, 143]	99 [66, 140]	117 [67, 163]	106 [78, 154]	0.003
Deep hypothermic cardiac arrest time, min.	20 [13, 32]	20 [13, 31]	23 [15, 38]	19 [12, 29]	<.001
Lowest temperature, Celcius	24 [20, 26]	24 [20, 26]	22 [18, 25]	23 [19, 26]	<.001
Cerebral perfusion strategy					0.163
- No cerebral perfusion	15% (361)	14% (297)	15% (37)	21% (27)	
- Unilateral antegrade	75% (1863)	75% (1582)	76% (187)	73% (94)	
- Bilateral antegrade	4.0% (100)	4.1% (86)	4.5% (11)	2.3% (3)	
- Retrograde	6.3% (157)	6.7% (142)	4.5% (11)	3.1% (4)	

Table 4. Outcomes data.

Variable	OVERALL (N=2481)	PRIMARY (N=2107)	REDO-AORTIC (N=246)	REDO-OTHER (N=128)	P value
POSTOPERATIVE OUTCOMES					
- Hospital mortality	10% (241)	9.3% (195)	11% (28)	14% (18)	0.132
- Cardiac reoperation for tamponade or bleeding	9.4% (233)	9.0% (190)	12% (29)	11% (14)	0.306
- Prolonged ventilation (> 40h)	19% (473)	18% (382)	22% (55)	28% (36)	0.008
- Dialysis dependent renal failure	5.6% (138)	5.2% (109)	5.7% (14)	12% (15)	0.007
- Deep sternal wound infection	0.69% (17)	0.62% (13)	0.41% (1)	2.3% (3)	0.061
- Any cerebrovascular accident	10% (255)	10% (220)	7.7% (19)	13% (16)	0.288
- STS modified composite endpoint (death, stroke, reop, renal failure, DSWI, long vent. > 40h)	31% (776)	30% (642)	34% (84)	39% (50)	0.075

Table 5. Outcomes of subgroup analysis.



Variable	PRIMARY-HEMI (N=1800)	REDO-HEM (N=266)I	P value	PRIMARY-TOTAL (N=307)	REDO-TOTAL (N=108)	P value
POSTOPERATIVE OUTCOMES						
- Hospital mortality	8.8% (159)	14% (36)	0.014	12% (36)	9.3% (10)	0.476
- Cardiac reoperation for tamponade or bleeding	8.3% (149)	10% (27)	0.306	13% (41)	15% (16)	0.713
- Prolonged ventilation (> 40h)	17% (302)	23% (61)	0.014	26% (80)	28% (30)	0.741
- Dialysis dependent renal failure	4.7% (85)	7.9% (21)	0.028	7.8% (24)	7.4% (8)	0.884
- Deep sternal wound infection	0.67% (12)	1.1% (3)	0.408	0.33% (1)	0.93% (1)	0.440
- Any cerebrovascular accident	10% (182)	10% (26)	0.867	12% (38)	8.3% (9)	0.250
- STS modified composite endpoint (death, stroke, reop, renal failure, DSWI, long vent. > 40h)	29% (515)	33% (89)	0.104	41% (127)	42% (45)	0.976
INTENSIVE CARE AND HOSPITAL STAY						
ICU length of stay (first stay), d	2.0 [1.0, 5]	2.9 [1.2, 6]	0.002	3.0 [1.1, 6]	3.1 [1.5, 8]	0.545
Hospital length of stay (first stay), d	8 [6, 14]	9 [6, 18]	0.007	10 [7, 21]	13 [7, 18]	0.290

**a**


Variables	OR	(95%CI)	P value
Reoperation	1.618	(1.322 to 1.980)	<.0001
Age (year)	1.532	(1.308 to 1.794)	<.0001
Peripheral vascular disease	1.578	(1.056 to 2.357)	0.0261
Cerebrovascular disease	1.626	(0.982 to 2.692)	0.0589
LVEF	0.971	(0.958 to 0.984)	<.0001
Acute aortic dissection	4.850	(3.831 to 6.139)	<.0001
Prolonged CPB time	4.752	(3.214 to 7.027)	<.0001

**b**

Variables	OR	(95%CI)	P value
Reoperation	1.318	(1.106 to 1.570)	0.0020
Age (year)	1.275	(1.150 to 1.413)	<.0001
Female	1.262	(1.025 to 1.553)	0.0281
Cerebrovascular disease	1.835	(1.232 to 2.734)	0.0028
Hypertension	1.407	(1.171 to 1.690)	0.0003
Coronary artery disease	1.470	(1.219 to 1.774)	<.0001
Aortic stenosis	0.630	(0.481 to 0.825)	0.0008
Renal failure	2.310	(1.512 to 3.530)	0.0001
LVEF	0.981	(0.972 to 0.991)	0.0003
Acute dissection or rupture	3.772	(2.996 to 4.751)	<.0001
Prolonged CPB time	3.324	(2.607 to 4.238)	<.0001
Cerebral ischemic time	1.689	(1.024 to 2.784)	0.0401
Total arch repair	1.575	(1.273 to 1.947)	<.0001



The Impact of Re-operation on Aortic Arch Reconstructive Surgery: a Multicentre, National Registry



	Primary	Redo	<i>p</i>
<b>HEMI-ARCH group</b>			
N.	1800	266	
Mortality	8.8 %	14 %	<b>0.014</b>
MMOM	29 %	33 %	0.104

	Primary	Redo	<i>p</i>
<b>TOTAL-ARCH group</b>			
N.	307	108	
Mortality	12 %	9.3 %	0.476
MMOM	42 %	42 %	0.976

From 2002 to 2021, nine centers

- **Primary** (2107) mortality: 9.3%
- **Redo-aortic** (246) mortality: 11%
- **Redo-other** (128) mortality: 14%

Independent predictors of mortality and MMOMs

Age over 65yrs

Acute dissection or rupture

Prolonged CPB time

Selected **aortic arch reoperations** can be performed safely in **experienced aortic centers** while further studies were needed for continuing optimization of surgical and patient management strategies.

